#Belgium #Gosselies #EZFuse system #Endo Tools Theraputics #endomina technology

Endo Tools Therapeutics Secures $23 Million for Endoscopic Solutions

Endo Tools Therapeutics (ETT) has made significant strides in the medical device arena by closing its Series C financing round, raising approximately $23 million. This funding will propel the commercialization of their innovative endomina® platform, which aims to transform treatment options for patients with obesity.

The Vision Behind Endo Tools Therapeutics

Founded with the mission to enhance medical treatments through advanced technologies, ETT focuses on developing endoscopic medical devices that minimize invasiveness while maximizing treatment effectiveness. The endomina platform, a centerpiece of the company, offers an intricate yet efficient solution adapted for standard endoscopic procedures.

The recent fundraising effort was primarily spearheaded by Capricorn Partners via their Capricorn Healthtech Fund II, with contributions from existing investors. Alexandre Chau, CEO of ETT, emphasized the importance of this financing, particularly in conjunction with the recent FDA clearance of the endomina® EZFuse system—an innovative product designed to simplify endoscopic workflows.

The Role of the Endomina EZFuse System

The endomina EZFuse system distinguishes itself by allowing physicians to easily perform suturing within the gastrointestinal tract through a natural orifice, specifically the mouth. This unique operation provides a more flexible and less invasive alternative to traditional surgical methods. The system is particularly notable as it enables the assembly on the endoscope within the stomach, thus optimizing surgeons’ access and operational space.

This upcoming technology is poised to support managing a significant number of patients grappling with Class I and II obesity—those who may be seeking alternatives to chronic GLP-1 therapies. By offering a minimally invasive procedure, patients can achieve effective results without the complications that often accompany traditional surgical interventions.

A Game-Changer in Clinical Efficiency

The newly cleared EZFuse system boasts a more intuitive design featuring a single-movement suturing mechanism. Early experiences indicate that this streamlined process leads to significantly faster suturing times, enabling doctors to complete procedures more efficiently without altering their usual techniques. This efficiency is crucial for optimizing operational capacities in both hospitals and ambulatory surgery centers while alleviating user fatigue and ensuring consistency in outcomes.

Filip Pintelon, Investment Partner at Capricorn Partners, highlighted the strategic significance of the EZFuse system’s FDA clearance and expressed excitement about supporting ETT at this transformative stage. The focus on enhancing the efficiency of gastrointestinal care using minimally invasive technologies could redefine current patient care practices, bringing about considerable advancements in medical treatment.

The Expanding Market Opportunity

As the demand for less invasive medical procedures surges, the market for advanced endoscopic suturing and tissue approximation is also witnessing robust growth. Millions of patients in the United States are currently left untreated due to the invasiveness associated with standard surgical options. The global inclination towards procedures offering reduced invasiveness is projected to fuel double-digit growth within the endoscopic suturing devices market.

With the innovative endomina platform and next-generation EZFuse system, ETT is well-positioned to capture a substantial share of this thriving multi-billion dollar industry, redefining how gastrointestinal surgeries are approached around the world.

Looking Ahead

Endo Tools Therapeutics is committed to paving the path toward improved obesity management through cutting-edge solutions. The financing milestone not only marks a new chapter in ETT's growth journey but also signifies a steadfast commitment to evolving patient care methodologies. Through rigorous clinical evidence collection and strategic scale-up efforts, ETT aims to further establish its presence across the U.S., Europe, and the Middle East.

For more information on Endo Tools Therapeutics and their innovative solutions, visit Endo Tools website.